title: Validation of the role of angiogenesis as a chemotherapeutic target.
authors.forename: Edward
authors.initials: E
authors.lastname: Chu
mesh_terms: D000222:Adaptation, Physiological; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000503:physiopathology*; D003131:Combined Modality Therapy; D018450:Disease Progression; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D009389:Neovascularization, Pathologic; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D014945:Wound Healing
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin